Andrea Foli

Pavia, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 57 publications

Eligibility criteria for clinical trials in AL amyloidosis result in exclusion of nearly half of real-world patients.

Eligibility criteria for clinical trials in AL amyloidosis result in exclusion of nearly half of real-world patients.

Journal: HemaSphere
Published: October 13, 2025

Acute coronary syndrome and coronary artery disease in wild-type transthyretin amyloid cardiomyopathy: a DIAMOND sub-study.

Acute coronary syndrome and coronary artery disease in wild-type transthyretin amyloid cardiomyopathy: a DIAMOND sub-study.

Journal: Journal of cardiovascular medicine (Hagerstown, Md.)
Published: September 16, 2025

Left ventriculo-arterial coupling in a contemporary cohort of patients with wild-type transthyretin cardiac amyloidosis treated with tafamidis.

Left ventriculo-arterial coupling in a contemporary cohort of patients with wild-type transthyretin cardiac amyloidosis treated with tafamidis.

Journal: Clinical research in cardiology : official journal of the German Cardiac Society
Published: April 12, 2025

Neurohormonal therapies at baseline and follow-up and survival in wild-type transthyretin cardiac amyloidosis.

Neurohormonal therapies at baseline and follow-up and survival in wild-type transthyretin cardiac amyloidosis.

Journal: Journal of cardiovascular medicine (Hagerstown, Md.)
Published: April 02, 2025

Predictors of Early Death in Patients With Wild-Type Transthyretin Cardiac Amyloidosis.

Predictors of Early Death in Patients With Wild-Type Transthyretin Cardiac Amyloidosis.

Journal: Journal of the American Heart Association
Published: December 24, 2024

Diagnostic Performance of the New Free Light Chain Ratio in Systemic Amyloidosis.

Diagnostic Performance of the New Free Light Chain Ratio in Systemic Amyloidosis.

Journal: JACC. CardioOncology
Published: December 17, 2024

Diffuse lung involvement as a rare presentation of systemic AL amyloidosis: a retrospective cohort study.

Diffuse lung involvement as a rare presentation of systemic AL amyloidosis: a retrospective cohort study.

Journal: Blood advances
Published: December 13, 2024

Daratumumab-based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case-control study.

Daratumumab-based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case-control study.

Journal: HemaSphere
Published: November 17, 2024

Feasibility of a Biomarker-Based Screening for Pre-Symptomatic AL Amyloidosis in Patients With Intermediate/High-Risk MGUS.

Feasibility of a Biomarker-Based Screening for Pre-Symptomatic AL Amyloidosis in Patients With Intermediate/High-Risk MGUS.

Journal: American journal of hematology
Published: October 09, 2024

Early diagnosis, disease stage and prognosis in wild-type transthyretin amyloid cardiomyopathy: The DIAMOND study.

Early diagnosis, disease stage and prognosis in wild-type transthyretin amyloid cardiomyopathy: The DIAMOND study.

Journal: ESC heart failure
Published: August 04, 2024

Delayed identification of monoclonal protein is associated with early death in isolated cardiac AL amyloidosis.

Delayed identification of monoclonal protein is associated with early death in isolated cardiac AL amyloidosis.

Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
Published: July 11, 2024

A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis.

A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis.

Journal: Hematological oncology
Published: March 11, 2024
Showing 1-12 of 57

Last Updated: 09/26/2026